Idiopathic Membranous Nephropathy Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Statistics, Revenue, Therapies, Companies by DelveInsight
Idiopathic Membranous Nephropathy companies include Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others.
(Albany, USA) DelveInsight's " Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Complicated Urinary Tract Infection (cUTI), historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection (cUTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Idiopathic Membranous Nephropathy market growth is driven by factors like increase in the prevalence of Idiopathic Membranous Nephropathy, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Idiopathic Membranous Nephropathy market report also offers comprehensive insights into the Idiopathic Membranous Nephropathy market size, share, Idiopathic Membranous Nephropathy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Idiopathic Membranous Nephropathy market size growth forward.
Some of the key highlights from the Idiopathic Membranous Nephropathy Market Insights Report:
The Idiopathic Membranous Nephropathy market size in the 7MM is expected to reach ~USD 1,000 million by 2034.
Several key pharmaceutical companies, including Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others, are developing novel products to improve the Idiopathic Membranous Nephropathy treatment outlook.
In 2023, the United States represented around 40% of all prevalent cases of Idiopathic Membranous Nephropathy across the 7MM. Data from Japan indicates that the prevalence of Idiopathic Membranous Nephropathy is expected to remain relatively stable from 2024 to 2034.
Among the EU4 countries and the UK, Germany had the highest prevalence of the condition, accounting for about 30% of cases, followed by the UK with approximately 20% in 2023. In the same year, PLA2R-specific cases in the EU4 and the UK made up about 75% of the total cases in the 7MM.
The market for Idiopathic Membranous Nephropathy (IMN) across the 7MM is projected to reach approximately USD 1,000 million by 2034. In 2023, the United States holds the largest market share, with around USD 88 million, compared to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. IMN is a major type of glomerular disease, marked by high protein levels in the urine (nephrotic syndrome) and is primarily autoimmune in nature.
Currently, there are no specific approved treatments for IMN, and management mainly involves supportive care. The market is expected to experience significant growth due to the increased use of existing drugs, the anticipated launch of new therapies, and growing awareness.
The total number of prevalent IMN cases in the 7MM is estimated to be about 71,000 in 2023. Of these, the US represents approximately 40% of the cases, while the EU4 and the UK together account for around 35%, and Japan contributes roughly 25%, making Japan the second-largest contributor after the US. Several promising drugs in the pipeline include TNT119, ALPN-303, MOR202, SNP-ACTH (1-39) Gel, and GAZYVA.
In December 2024, SynAct Pharma Aps announced results of an Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe Proteinuria
In October 2023, Human Immunology Biosciences (HI-Bio) received FDA's Breakthrough Therapy designation for felzartamab to treat primary membranous nephropathy.
In June 2023, the FDA granted orphan drug designation to SNP-ACTH (1-39) gel for primary membranous nephropathy. Additionally, Biogen completed its acquisition of HI-Bio in July 2024.
In June 2022, HI-Bio and MorphoSys AG entered into a licensing agreement for the development and commercialization of MorphoSys' anti-CD38 antibody, felzartamab.
In the 7MM, MOR202 (felzartamab) is projected to generate the highest market revenue, reaching around USD 500 million by 2034. Within the EU4 and the UK, Germany had the largest market size, totaling approximately USD 10 million in 2023.
As per DelveInsight analysis, the Idiopathic Membranous Nephropathy market is anticipated to witness growth at a considerable CAGR
Idiopathic Membranous Nephropathy Overview
Idiopathic Membranous Nephropathy (IMN) is a common form of glomerular disease primarily linked to nephrotic syndrome. It occurs when the immune system attacks the glomeruli, resulting in significant protein loss in the urine, swelling, and the potential for kidney failure. The condition is labeled "idiopathic" when no clear secondary cause is identified, though it can be triggered by various underlying factors such as autoimmune diseases or infections. IMN generally affects adults, especially middle-aged men, and presents with symptoms like frothy urine, swelling in the legs and abdomen, and weight gain due to fluid buildup.
Diagnosing IMN involves both clinical evaluation and laboratory tests. Initial tests include urine analysis to detect high levels of protein (usually over 3.5 g/day), which is characteristic of nephrotic syndrome. Blood tests are used to assess kidney function and identify hypoalbuminemia and dyslipidemia, both common in nephrotic syndrome. A kidney biopsy is often needed to confirm the diagnosis, revealing typical changes in the glomeruli, such as immune complex deposits along the capillary walls. Additionally, serological tests for specific antibodies, like those targeting the phospholipase A2 receptor (PLA2R), can help distinguish primary IMN from secondary forms, aiding in the development of appropriate treatment plans.
Idiopathic Membranous Nephropathy Epidemiology Segmentation
DelveInsight's Idiopathic Membranous Nephropathy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Idiopathic Membranous Nephropathy historical patient pools and forecasted Idiopathic Membranous Nephropathy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Idiopathic Membranous Nephropathy Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
Idiopathic Membranous Nephropathy Prevalence
Age-Specific Idiopathic Membranous Nephropathy Prevalence
Gender-Specific Idiopathic Membranous Nephropathy Prevalence
Diagnosed and Treatable Cases of Idiopathic Membranous Nephropathy
Idiopathic Membranous Nephropathy Market Outlook
The Idiopathic Membranous Nephropathy (IMN) market is driven by several key factors, including the rising prevalence of chronic kidney diseases globally, improved diagnostic capabilities enabling early detection, and increased awareness among physicians and patients. The development of novel biomarkers and targeted biologics, along with the growing adoption of personalized medicine approaches, are also fueling market growth. Additionally, supportive reimbursement policies and ongoing clinical trials exploring innovative therapies contribute to market expansion. However, significant barriers persist, such as the high cost of advanced treatments and limited accessibility in low- and middle-income regions. The heterogeneity of disease progression complicates clinical management, often delaying optimal intervention. Moreover, stringent regulatory requirements and lengthy approval timelines for new therapeutics pose challenges for manufacturers. A lack of comprehensive long-term safety data on emerging therapies and concerns regarding potential adverse effects further restrict widespread adoption. Together, these drivers and barriers shape the evolving landscape of the IMN market, highlighting both opportunities for advancement and areas requiring strategic focus to address unmet needs.
Major companies like Hoffmann-La Roche, HI-Bio, Cerium Pharmaceuticals, BeiGene, and others are advancing their lead candidates through various stages of clinical development, with the goal of exploring their products for the treatment of Idiopathic Membranous Nephropathy.
Idiopathic Membranous Nephropathy Emerging Drugs
Idiopathic Membranous Nephropathy Key Companies
Bristol Myers Squibb Company, Merck and Co Inc., Mylan Pharmaceutical ltd., Novartis AG, Pfizer Inc., Roche, Aspen Global Inc., Astellas Pharma Inc., Baxter Healthcare Corporation, Sigma Aldrich Corporation, and others
Scope of the Idiopathic Membranous Nephropathy Market Report:
10 Years Forecast
7MM Coverage
Descriptive overview of Idiopathic Membranous Nephropathy, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Idiopathic Membranous Nephropathy epidemiology in the 7MM
Idiopathic Membranous Nephropathy marketed and emerging therapies
Idiopathic Membranous Nephropathy companies
Idiopathic Membranous Nephropathy market drivers and barriers
Table of Contents:
1 Idiopathic Membranous Nephropathy Market Key Comprehensive Insights
2 Idiopathic Membranous Nephropathy Market Report Introduction
3 Competitive Intelligence Analysis for Idiopathic Membranous Nephropathy
4 Idiopathic Membranous Nephropathy Market Analysis Overview at a Glance
5 Executive Summary of Idiopathic Membranous Nephropathy
6 Idiopathic Membranous Nephropathy Epidemiology and Market Methodology
7 Idiopathic Membranous Nephropathy Epidemiology and Patient Population
8 Idiopathic Membranous Nephropathy Patient Journey
9 Idiopathic Membranous Nephropathy Treatment Algorithm, Idiopathic Membranous Nephropathy Current Treatment, and Medical Practices
10 Key Endpoints in Idiopathic Membranous Nephropathy Clinical Trials
11 Idiopathic Membranous Nephropathy Marketed Therapies
12 Idiopathic Membranous Nephropathy Emerging Therapies
13 Idiopathic Membranous Nephropathy: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Idiopathic Membranous Nephropathy
16 Idiopathic Membranous Nephropathy Market Key Opinion Leaders Reviews
18 Idiopathic Membranous Nephropathy Market Drivers
19 Idiopathic Membranous Nephropathy Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
29 minutes ago
- Globe and Mail
Prediction: 2 Artificial Intelligence (AI) Stocks That Will Be Worth More Than Nvidia by 2030
Key Points Nvidia has been the biggest beneficiary of AI spending among big tech companies. But Amazon and Meta Platforms are two tech giants seeing very strong results from investments in AI, and their future could be even brighter. Both trade at compelling valuations, especially compared to how expensive Nvidia has become. 10 stocks we like better than Amazon › Since October 2022, Nvidia has seen its value increase by more than $4 trillion. To put that into perspective, no other company is even worth $4 trillion today. The huge surge in value for the maker of graphics processing units (GPUs) stems from a few big tech companies spending hundreds of billions on its chips every year. The four biggest hyperscalers are set to spend around $380 billion on AI infrastructure this year, and they have guided for significant steps up in spending next year. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Nvidia is set to be the prime beneficiary of that increased spending for some time, but that doesn't mean the stock will continue to climb. Market prices are based on what investors expect in the future, and the expectations for Nvidia remain high. But two other AI stocks look like they could surpass investor expectations, pushing both companies to exceed Nvidia's value by 2030. Can Nvidia keep climbing from here? Continued growth in AI spending is giving investors more and more confidence that Nvidia can keep up its torrid sales growth. The three main public cloud providers all reiterated that demand exceeds computing capacity, which means they will continue to spend growing amounts to meet their customers' needs. Meanwhile, Nvidia is selling chips as fast as it can make them. That led to a 69% rise in revenue in the company's first quarter, and a 59% increase in adjusted income. But it's unlikely to see growth continue at this pace. All four hyperscalers are working on custom silicon solutions for their own AI training. Microsoft is reportedly planning to shift a significant portion of its spending to its Maia300 chip in late 2026. Meta Platforms (NASDAQ: META) is working on expanding the AI workloads that its custom Meta Training and Inference Accelerating (MTIA) chips can handle. And on top of all of that, AMD is starting to show progress in catching up to Nvidia, while continuing to offer excellent price performance. Investors should expect a significant slowdown in sales as Nvidia faces fierce competition for its share of data center servers and it battles with the law of large numbers. As supply-demand forces reach equilibrium, the chipmaker might not be able to command such high gross margins, either. That could weigh on earnings growth. But with the stock currently trading at more than 42 times forward earnings, investors seem to think those risks aren't going to materialize. I think it's more likely they will keep Nvidia from continuing to outperform the market at such a torrid pace, limiting how much more upside there is from here. If investors want to buy shares of a big tech company capitalizing on the growth of AI, the following two industry giants present better value with more upside. In fact, I expect they will both be worth more than Nvidia by 2030. 1. Amazon Amazon (NASDAQ: AMZN) is the largest provider of public cloud computing in the world with Amazon Web Services (AWS), making it one of Nvidia's biggest customers. While the company was caught flat-footed as generative AI took off in 2022, management quickly caught up with the competition thanks in part to its investment in Anthropic. Management continues to see strong demand for its AI services, with revenue more than doubling year over year. However, AWS's scale has masked that strong growth. The cloud services segment generated $116 billion in revenue over the last 12 months. That's roughly 55% larger than its next closest competitor, Microsoft. But AWS's 17% year-over-year growth looks disappointing compared to Microsoft's 39% growth in cloud services last quarter. Nonetheless, Amazon has mostly kept its market share despite strong growth by its competitors. What's more important is that the margin profile on AWS is extremely strong. The operating margin of 36.8% over the last 12 months is up from 33.4% a year ago. And while it took a dip in the second quarter, that's due to the timing of share-based compensation. The long-term trend shows continued improvement in margins. Meanwhile, Amazon's retail business is becoming very profitable in its own right. The North American segment saw its operating margin climb to 7% last quarter while the international segment's margin came in at 3.4%. Strong top-line growth of 11% for both helped, which was bolstered by high-margin ad revenue growth of 22%. The long-term trends favor steady revenue growth across Amazon's businesses with particular strength in its high-margin operations (namely AWS and advertising). That should result in earnings growth well above average. And as its spending growth on AWS slows down, free cash flow should rise to new records by the end of the decade. That gives the company more opportunities to invest for growth, just as it has managed to do throughout its history. The stock currently looks attractive amid a small pullback in price. 2. Meta Platforms Meta is another major Nvidia customer, but unlike Amazon, it only uses Nvidia chips for its own AI needs. In fact, it might be spending more on its own AI needs than any other company in the world. And Meta's second-quarter results are a clear example of why it's willing to spend so much. Sales grew 22% last quarter, and its operating margin expanded 5 percentage points. For some perspective, that's faster revenue growth than both Snap and Pinterest despite being a much bigger force in social media advertising. Meta's AI capabilities are a clear reason for the outperformance. Artificial intelligence has led to better recommendations for both advertisements and organic content. As a result, the company served up more ads and was able to command higher pricing per ad impression. Meanwhile, it's seeing strong uptake of its generative AI tools for ad creation, which makes it easier for marketers to create and test new ideas. There are a number of other opportunities that AI could unlock. Those include AI chatbots for businesses in WhatsApp and Messenger, which could drive increased click-to-message ads in Facebook and Instagram. And management has said its Meta AI chatbot built into its apps now has 1 billion monthly active users, giving it yet another surface to monetize with ads. It only recently started showing ads in WhatsApp and Threads. That should give it room to grow supply as demand increases due to its generative AI tools making advertising easier. Lastly, Meta is at the forefront of development in augmented and virtual reality. AI can unlock a lot of value in an environment that's also aware of your surroundings. The company has already seen strong early adoption of its Meta Glasses with AI built in. Shares look very attractive with an enterprise value around 16 times forward estimates on earnings before interest, taxes, depreciation, and amortization (EBITDA). While depreciation of its data centers will weigh on its margins, the company is proving the investments are paying off with very strong revenue growth and by unlocking a lot of potential profits in the long run. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
34 minutes ago
- Globe and Mail
Thinking of Buying Tesla Stock? Here Are 2 Red Flags to Watch
Key Points Tesla's heavy reliance on Elon Musk adds significant leadership risk. Increasing competition from established automakers and Chinese EV makers is pressuring Tesla's dominance. Investors need to be comfortable with Tesla's high valuation. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) has long been the front runner in the electric vehicle (EV) revolution in the U.S. Its innovation, brand strength, and rapid growth have made it a favorite among investors. Yet, despite its impressive track record, there are two big risks that investors should carefully consider before buying Tesla stock today. 1. The Elon Musk factor Elon Musk 's leadership is often cited as Tesla's greatest strength -- and, paradoxically, one of its most significant vulnerabilities. Musk's vision and hands-on approach have driven Tesla's technological breakthroughs and ambitious expansion. However, this heavy reliance on a single individual introduces what investors refer to as "key man risk." If Musk were to step back from daily operations or shift his focus to other projects, Tesla might face challenges in maintaining its momentum. Though Tesla's management team has grown stronger, few executives command the same vision, drive, and public attention as Musk. Recently, Musk's increasing involvement in political activities has raised concerns about potential distractions or reputational risks for Tesla. While the company has remained operationally strong, these developments underscore the uncertainty around its future leadership continuity. While Tesla's success lies not only with Musk but also with his team, which has executed well on his vision -- no one can build a trillion-dollar company alone -- there is still no clear successor (or a viable management team) . The silver lining here is that the Tesla board has become more serious about finding one in recent months, largely due to the CEO's active involvement in politics. For investors, this means that Tesla's fortunes remain closely tied to Musk's presence and decisions -- a factor that adds a layer of risk to the investment. 2. Intensifying competition Tesla might have been an early mover in the EV industry, but its dominance is no longer guaranteed. The industry landscape is rapidly evolving, with legacy automakers and new entrants accelerating their electric ambitions. Companies like Ford and General Motors are aggressively expanding their EV lineups. For instance, Ford plans to introduce a $30,000 midsize truck by 2027. That price is significantly lower than the average for an EV, and Ford is investing $5 billion in its EV production to make it happen. GM, on the other hand, is working hard on next-generation battery technologies to improve range, charging performance, and cost. Meanwhile, Chinese manufacturers such as BYD are growing their international footprints, particularly in Europe, where Tesla experienced a nearly 27% sales declinein July 2025. BYD's battery technology, government support, and competitive pricing make it a formidable challenger. In addition, a host of EV start-ups are innovating in battery tech, autonomous driving, and new business models, further intensifying competition. While Tesla is not sitting still -- it is working on becoming the lowest-cost producer by cutting prices to grow sales volume and achieve economies of scale -- there is no guarantee that it can maintain its market share over time. In short, it's no longer the only player in town. What does this mean for investors? Tesla's story remains compelling: It's a pioneer with a powerful brand, innovative products, and potential optionality with some of its long shot bets (robotaxi, humanoid robots, etc). But the key man risk surrounding Musk and the escalating competitive landscape are real concerns that investors can't ignore. If Tesla continues to innovate more rapidly than its rivals, the company could sustain its growth trajectory. However, any leadership changes or slips in market position could hurt the business and its share price. While these two risks don't necessarily call for the sale of the stock, they do mean that investors should think carefully before buying the stock today. Tesla stock trades at a significant premium valuation to other carmakers. For perspective, Tesla has a price-to-sales (P/S) ratio of 12.9, compared to GM's 0.3. Unless you're comfortable with the risks and the high valuation, buying the stock today may not be a prudent decision. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $467,985!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $44,015!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $668,155!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon. See the 3 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
34 minutes ago
- Globe and Mail
Virtual Flip Formula Launches Rebranded Mentorship Program for New Real Estate Wholesalers
Phoenix, Arizona--(Newsfile Corp. - August 17, 2025) - Virtual Flip Formula, a real estate education company founded by Tyson Smith, has announced the formal launch and rebranding of its mentorship-based training program for aspiring real estate wholesalers. Based in Phoenix, Arizona, the company provides remote coaching and support designed for individuals seeking to break into the real estate industry without the need to purchase or own property. To view an enhanced version of this graphic, please visit: A Streamlined Approach to Entry-Level Real Estate Business Models Virtual Flip Formula focuses on real estate wholesaling - a model where individuals earn fees by connecting property sellers with buyers. This approach allows participants to operate without purchasing real estate themselves, which makes the model accessible to those without substantial upfront capital. Rather than relying on traditional real estate investment strategies that require financing or ownership, Virtual Flip Formula provides an alternative route that emphasizes hustle, outreach, and structured negotiation. From Informal Demand to Structured Support The concept originated after founder Tyson Smith began receiving requests from his social media audience to share how he had built his wholesaling business. What began as informal guidance grew into a structured program featuring weekly coaching calls, digital tools, and peer support. "Once I saw the kind of life-changing results people were getting after learning the process, I knew there was an opportunity to build something more formal and supportive," said Tyson Smith, CEO of Virtual Flip Formula. The company initially launched in 2023 but underwent a rebrand and operational refinement in early 2025 to better align with the needs of its growing student base. To view an enhanced version of this graphic, please visit: Program Designed for Accessibility and Sustainability The mentorship program includes weekly coaching sessions, operational frameworks, and guided exercises aimed at helping new wholesalers close their first deal. According to the company, the core objective is to take students from zero experience to generating consistent income through repeatable systems. "What sets our model apart is the focus on accessibility," said Smith."Most beginners don't have tens of thousands in capital to purchase real estate. With wholesaling, you don't need to. What you need is structure, support, and the discipline to take action." Building a Supportive Community of First-Time Wholesalers Looking ahead, Virtual Flip Formula plans to support over 1000 new wholesalers in closing their first deal within the next 12 to 24 months. Long-term, the company aspires to build a national community where students can share resources, partner on deals, and create business momentum together. "We're creating an environment where students aren't just learning from us - they're learning from each other," Smith noted."It's about building something that lasts beyond one course or one deal." About Virtual Flip Formula Virtual Flip Formula is a mentorship-based program designed to help beginners launch real estate wholesaling businesses. The company operates remotely and provides coaching, strategy, and support for aspiring entrepreneurs seeking a practical entry point into the real estate industry. To follow Tyson Smith's work, connect with him on Instagram or YouTube. Media Contact
